A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies.
Latest Information Update: 17 Jun 2019
Price :
$35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Solid tumours; Thyroid cancer
- Focus Adverse reactions; Pharmacokinetics
- 02 Jun 2013 Long-term follow-up results in patients with progressive, metastatic medullary thyroid cancer presented at ASCO 2013, according to an Exelixis media release.
- 26 Feb 2013 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.
- 26 Feb 2013 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.